Future directions in the management of small cell lung cancer

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The treatment of small cell lung cancer (SCLC) has continued to evolve over the past 20 years and now consists primarily of combination chemotherapy with or without thoracic radiotherapy depending on stage at presentation. However, despite marked improvement in overall survival, a majority of patients continue to die of their disease. It is not likely that conventional chemotherapy agents will substantially alter this dismal fact but new agents are available with novel mechanisms of action some of which yield excellent response rates. The agents with greatest promise include the taxanes and drugs that target topoisomerase I. Real progress in the management of SCLC will come with the identification of methods for overcoming drug resistance, exploration of new treatment strategies including gene therapy and possibly through the use of biological agents. Chemoprevention trials are of the utmost importance given the high incidence of second primary tumors that arise in the few long term survivors of this disease. All these areas are fertile grounds for future investigation in the management of SCLC.

Original languageEnglish (US)
JournalLung Cancer
Volume12
Issue numberSUPPL. 3
DOIs
StatePublished - 1995

Fingerprint

Small Cell Lung Carcinoma
Taxoids
Type I DNA Topoisomerase
Chemoprevention
Biological Factors
Combination Drug Therapy
Drug Resistance
Genetic Therapy
Survivors
Radiotherapy
Thorax
Drug Therapy
Survival
Incidence
Therapeutics
Pharmaceutical Preparations
Direction compound
Neoplasms

Keywords

  • Chemotherapy regimes
  • Future directions
  • Small cell lung cancer
  • Small cell lung cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Future directions in the management of small cell lung cancer. / Johnson, D. H.

In: Lung Cancer, Vol. 12, No. SUPPL. 3, 1995.

Research output: Contribution to journalArticle

@article{eac85bfcfae94196a1c99a884aa3c320,
title = "Future directions in the management of small cell lung cancer",
abstract = "The treatment of small cell lung cancer (SCLC) has continued to evolve over the past 20 years and now consists primarily of combination chemotherapy with or without thoracic radiotherapy depending on stage at presentation. However, despite marked improvement in overall survival, a majority of patients continue to die of their disease. It is not likely that conventional chemotherapy agents will substantially alter this dismal fact but new agents are available with novel mechanisms of action some of which yield excellent response rates. The agents with greatest promise include the taxanes and drugs that target topoisomerase I. Real progress in the management of SCLC will come with the identification of methods for overcoming drug resistance, exploration of new treatment strategies including gene therapy and possibly through the use of biological agents. Chemoprevention trials are of the utmost importance given the high incidence of second primary tumors that arise in the few long term survivors of this disease. All these areas are fertile grounds for future investigation in the management of SCLC.",
keywords = "Chemotherapy regimes, Future directions, Small cell lung cancer, Small cell lung cancer",
author = "Johnson, {D. H.}",
year = "1995",
doi = "10.1016/0169-5002(95)00422-W",
language = "English (US)",
volume = "12",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Future directions in the management of small cell lung cancer

AU - Johnson, D. H.

PY - 1995

Y1 - 1995

N2 - The treatment of small cell lung cancer (SCLC) has continued to evolve over the past 20 years and now consists primarily of combination chemotherapy with or without thoracic radiotherapy depending on stage at presentation. However, despite marked improvement in overall survival, a majority of patients continue to die of their disease. It is not likely that conventional chemotherapy agents will substantially alter this dismal fact but new agents are available with novel mechanisms of action some of which yield excellent response rates. The agents with greatest promise include the taxanes and drugs that target topoisomerase I. Real progress in the management of SCLC will come with the identification of methods for overcoming drug resistance, exploration of new treatment strategies including gene therapy and possibly through the use of biological agents. Chemoprevention trials are of the utmost importance given the high incidence of second primary tumors that arise in the few long term survivors of this disease. All these areas are fertile grounds for future investigation in the management of SCLC.

AB - The treatment of small cell lung cancer (SCLC) has continued to evolve over the past 20 years and now consists primarily of combination chemotherapy with or without thoracic radiotherapy depending on stage at presentation. However, despite marked improvement in overall survival, a majority of patients continue to die of their disease. It is not likely that conventional chemotherapy agents will substantially alter this dismal fact but new agents are available with novel mechanisms of action some of which yield excellent response rates. The agents with greatest promise include the taxanes and drugs that target topoisomerase I. Real progress in the management of SCLC will come with the identification of methods for overcoming drug resistance, exploration of new treatment strategies including gene therapy and possibly through the use of biological agents. Chemoprevention trials are of the utmost importance given the high incidence of second primary tumors that arise in the few long term survivors of this disease. All these areas are fertile grounds for future investigation in the management of SCLC.

KW - Chemotherapy regimes

KW - Future directions

KW - Small cell lung cancer

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0029002901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029002901&partnerID=8YFLogxK

U2 - 10.1016/0169-5002(95)00422-W

DO - 10.1016/0169-5002(95)00422-W

M3 - Article

C2 - 7551959

AN - SCOPUS:0029002901

VL - 12

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - SUPPL. 3

ER -